

جامعة الاسراء

نموذج التفويض

أنا ضحى محسن عبدالحسين الظالمي، أفوض جامعة الاسراء بتزويد نسخ من رسالتي للمكتبات أو المؤسسات أو الهيئات أو الأشخاص عند طلبهم حسب التعليمات النافذة في الجامعة.

التوقيع: 

التاريخ: 2020 / 6 / 11

**Isra University**

**Authorization Form**

I'm Dhuha Mohsin Abdulhussein Al-Dhalemi, authorize Al-Isra University to supply copies of my Thesis to libraries or establishments or individuals on request, according to Al-Isra University regulations.

Signature: 

Date: 11/6/2020

**Synthesis and characterization of quinazoline-cinnamic acid hybrid as  
Alzheimer's drug candidate**

By

**Dhuha Mohsin Abdulhussein Al-Dhalemi**

Supervisor

**Dr. Zead Abudayeh**

A Thesis

**Submitted to Faculty of Pharmacy as a Partial Fulfillment of the Requirements for the  
Master's Degree in Pharmaceutical Sciences**

**Faculty of Pharmacy**

**Isra University**

**June, 2020**

## COMMITTEE DECISION

This Thesis (Synthesis and characterization of quinazoline-cinnamic acid hybrid as Alzheimer's drug candidate) was Successfully Defended and Approved on -----

### Examination Committee

### Signature


Dr. Zead Helmi Abudayeh, (Supervisor)  
Assistant Professor of Pharmaceutical Chemistry  
and Pharmacognosy.  
Isra University



Dr. Samer Hasan Hussein-Al-Ali (Member),  
Associate Professor of Nanosciences,  
Isra University



Dr. Eyad Mazin Mallah (Member).  
Professor of Pharmaceutical Organic Chemistry,  
Faculty of Pharmacy and Medical Sciences,  
Petra University



## **Dedication**

This work dedicated to my parents, family, friends and lovely people. To my father and my first supervisor, Muhsin Al-Dhalemi, for his love, caring and sacrifices for educating and preparing me for my future. He always being my supporter and a source of light in life. To my mother, for her prayers, love and kindness, for being in my side in all circumstances, for listening to me, for her patience while I was abroad and for being my friend around my life. To my lonely sister, for her lovely heart, for being my pressure release with her pure soul and for her support through it all. To my lovely brothers, Ahmed and Redha, for their emotional support. To my close friend, Fatima, for sharing me all the years past with difficulties and joys. She, for months past, has encouraged me attentively with her fullest and truest attention to accomplish my work with truthful self-confidence.

## Acknowledgment

First and foremost, thanks to the almighty God, for his blessing during my study work to complete the work effectively.

I'd like to express my sincere and deep gratitude to my study supervisor, Dr. Zead Helmi Abudayeh, for his dynamism, vision, sincerity and motivation. He had been taught me the methodology to make the research and to present its work clearly. It was a great honor and pleasure to study under his supervision. I'm really thankful for what he had been offered me.

I'd like also to thank Isra University for this opportunity and to thank all professors and mentors for their kindness. Specially Dr.Qais Abualassal for his supporting, encouraging and education that he gave me during this project.

As well I'd like the committee members, Dr.Eyad Mazin Mallah and Dr. Samer Hasan Hussein-Al-Ali for their kindness and all the notes that ride this project to the right way.

## Table of Contents

Committee Decision.....	iii
Dedication .....	iv
Acknowledgment .....	v
Table of Contents .....	vi
List of Tables .....	viii
List of Figures.....	ix
List of Schemes.....	x
List of Abbreviations.....	xi
Abstract .....	xiv
1. Introduction .....	2
1.1 Signs and symptoms .....	2
1.2 Current treatment for AD.....	2
1.3 Pathological hypothesis of Alzheimer's disease .....	3
1.3.1 Cholinergic hypothesis.....	3
1.3.2 Oxidative hypothesis.....	4
1.3.3 Amyloid beta hypothesis .....	5
1.4 Quinazolines.....	5
1.5 Cinnamic acid.....	6
1.6 Aim of the work .....	8
2. Review articles.....	10
3. Materials and method .....	15
3.1 Materials.....	15
3.2 Methods .....	15
3.2.1 Thin layer chromatography (TLC): .....	15
3.2.2 Gas chromatography–mass spectrometry (GC-MS) .....	16

3.2.3 Crystallization .....	16
3.2.4 Nuclear magnetic resonance (NMR) .....	17
4. Experimental.....	19
4.1 Synthesis of 2-methylaminobenzamide (2). ....	19
4.2 Synthesis of 1'-methyl-3', 4'-dihydro-1'H-spiro [cyclopentane-1, 2'- quinazoline] (3). ....	21
4.3 Synthesis of 1'-methyl-3', 4'-dihydro-1'H-spiro [cyclopentane-1, 2'- quinazoline] (4). ....	23
4.4 Synthesis of compound (5).....	25
5. Results and Discussion .....	29
6. Conclusions and recommendations .....	34
6.1 Conclusions.....	34
6.2 Recommendations .....	34
References .....	36
Abstract (Arabic) .....	40

**List of tables**

Number	Table caption	Page
1	Reaction conditions for the synthesis of compound <b>5</b> using DCC.	31
2	Optimization of the reaction conditions used for compound <b>5</b> synthesis.	32



## List of figures

Number	Figure caption	page
1	Schematic representation of AChE binding sites.	4
2	General structure of quinazoline.	6
3	Structure of cinnamic acid.	6
4	Structure of DHED (1), structure of rutacarpine (2), structure of tacrine(3).	10
5	Structure of 2, 3-dihydroquinazolin-4(1H)-one derivatives, 12: structure of Quinazolin-4(3H)-one derivatives, 3: structure of 2, 4-disubstituted quinazoline derivatives.	11
6	Structure of cinnamic-N-Benzylpiperidines hybrids, cinnamic-N,N-Dibenzyl (N-methyl) amine hybrids.	12
7	Structure of tacrine-cinnamic acid hybrid.	13
8	GC-MS machine.	16
9	GC-MS spectrum of compound <b>2</b> .	20
10	GC-MS spectrum of compound <b>3</b> .	22
11	GC-MS spectrum of compound <b>4</b>	24
12	GC-MS spectrum of compound <b>5</b> .	26
13	C <sup>13</sup> -NMR and H <sup>1</sup> -NMR of compound <b>5</b> .	27

**List of schemes**

<b>Number</b>	<b>Scheme caption</b>	<b>page</b>
1	Synthesis of quinazoline-cinnamic acid hybrid molecule.	8
2	Synthesis of compound <b>2</b> .	19
3	Synthesis of compound <b>3</b> .	21
4	Synthesis of compound <b>4</b> .	23
5	Synthesis of compound <b>5</b> .	25
6	Mechanism of reaction for the synthesis of compound <b>3</b> .	29
7	Mechanism of reaction for the synthesis of compound <b>4</b> .	30
8	Anhydride preparation and consecutive coupling with amines.	32
9	Mechanism of amide formation using SOCl <sub>2</sub> .	32

**List of abbreviations or symbols**

Abbreviations or symbols	Definition
AD	Alzheimer's disease
ACh	Acetylcholine
AChEI	Acetyl cholinesterase inhibitors
AChEs	Acetyl cholinesterase
A $\beta$	Beta – amyloid
BChEs	Buteryl cholinesterases
CDCl <sub>3</sub>	Deuterated chloroform
DCM	Dichloromethane
DHED	Dehydroevodiamine hydrochlorid
DPPH	2,2-diphenyl-1-picrylhydrazyl
eq	Equivalent
FDA	Food and Drug Administration
FID	Flame ionization detection

GC-MS	Gas chromatography-mass spectroscopy
H <sub>2</sub> O	Water
H <sub>2</sub> O <sub>2</sub>	Hydrogen peroxide
Hr	Hour
IR	Infra-red spectroscopy
LiAlH <sub>4</sub>	Lithium Aluminum hydride
N <sub>2</sub> O <sub>3</sub>	Di-nitrogen trioxide
Na <sub>2</sub> SO <sub>4</sub>	Sodium Sulfate
NaOH	Sodium hydroxide
NMR	Nuclear magnetic resonance spectroscopy
<i>p</i> -TSA	Toluene-4-sulfonic acid monohydrate
RF	Retardation Factor
RNS	Reactive nitrogen species
ROS	Reactive oxygen species
SAR	Structure Activity relationships

SOCl <sub>2</sub>	Thionyl chloride
TEA	Triethyl amine
THF	Tetrahydrofuran
TLC	Thin-layer chromatography
TMSCl	Trimethylsilyl chloride
<i>t<sub>R</sub></i>	Retention time
EtOAc	Ethyl acetate
UV	Ultra- Violet

# **Synthesis and characterization of quinazoline-cinnamic acid hybrid as Alzheimer's drug candidate**

By

**Dhuha Muhsin Al-Dhalemi**

Supervisor

**Dr. Zead Abudayeh**

## **Abstract**

Alzheimer's disease (AD) has been one of the most important cause of death for elderly people around the world. It's characterized by cognitive impairment and memory loss, mainly because of damage of cholinergic neurons in the fore-brain and hippocampus and reducing amount of Acetylcholine as well, the second main cause is the oxidative stress by reactive oxygen species (ROS) and reactive nitrogen species (RNS) in many brain region. Current treatment available for this neurodegenerative disease was mainly symptomatic and they were not affected on disease progression. Quinazoline moiety as promising structure in many research has the ability to inhibit acetylcholine esterase (AChE) enzyme and the ability of free radical scavenging. We decided to design and synthesize a novel hybrid compound **5** (quinazoline- cinnamic acid) that supposed to have a dual biological activity to delay the progression of AD. Synthesis of final hybrid compound was done through several reaction starting from N-methylisatoic anhydride which reacted with aqueous ammonia to form compound **2** with 90% yield. Second step involved synthesis of spiro compound (**3**) with 90% yeild by reacted compound **2** with cyclopentanone. Compound **4** was

synthesized with 94% yield by reduction of compound **3** using  $\text{LiAlH}_4$  and compound **5** was synthesized in 46% of yield. All reactions involved was monitored using TLC and GC-MS and characterized their final product by H-NMR and C-NMR. In future, the hybrid compound **5** as potential drug candidate for AD could be biologically evaluated for its ability to inhibit AChE enzyme and its antioxidant activity.